![](images/graphics/blank.gif)
Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma
14
lượt xem 1
download
lượt xem 1
download
![](https://tailieu.vn/static/b2013az/templates/version1/default/images/down16x21.png)
Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) pathway with the MEK inhibitor, trametinib (Tra) have been limited by toxicities and the development of resistance.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
![](images/graphics/blank.gif)
CÓ THỂ BẠN MUỐN DOWNLOAD